NCT00161291View on ClinicalTrials.gov

Open Label Trial for Post-Menopausal Women With Newly Diagnosed Operable Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

November 30, 2006

Study Completion Date

November 30, 2006

Conditions
Breast Cancer
Interventions
DRUG

Letrozole in combination with Bevacizumab

Patients will be administered Letrozole at 2.5 mg PO a day and Avastin at 15 mg/kg IV every 3 weeks for 24 weeks. Patients will then undergo surgical treatment and receive adjuvant therapy according to the treating physician.

Trial Locations (1)

35294

University of Alabama at Birmingham, Birmingham

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

University of Alabama at Birmingham

OTHER